KWF
Lead4Life PPP 2026 – Lead-212 Radiopharmaceutical Development
12:00 noon; full proposal phase. Matchmaking phase precedes full proposal. Institutes not yet registered must submit a GMS registration request at least 6 weeks before closing.
Last verified:
Details
| Funder | KWF |
| Budget | €0.5M–€2M per project (total programme budget €5M) |
| Deadline | 22 September 2026 |
| Duration | Up to 4 years |
| Consortium | Required — public-private partnership (PPP); consortium agreement between all participants mandatory |
| Application | 2-stage: matchmaking phase → full proposal (submitted via KWF GMS by 22 September 2026) |
| TRL | 1-7 |
| Frequency | One-off |
| Eligible countries | NL |
Eligibility & scope
Health~Holland PPP programme (KWF, NRG PALLAS, FAST, Oncode Institute) for lead-212 radiopharmaceutical R&D. Proposals must include a private party (PPP requirement); private party must not be an undertaking in difficulty (RVO declaration required). Projects must comply with Health~Holland PPP requirements and participate in Lead4Life governance/national TRT network. Dutch Summary reviewed by Patient Advisory Committee (PACO).
Related on Grantsby
- KWF writing tips & FAQ
Evaluation criteria, proposal structure, common mistakes.
More from KWF
KWF Proof of Concept 2026-PoC-2
Deadline: 2 Jun 2026Up to €150,000 incl. VATProof Of Concept 2026-2
Deadline: 2 Jun 2026KWF Proof of Concept (PoC) Programme – Call 2026-PoC-2
Deadline: 2 Jun 2026Up to €150,000 incl. VATINTER-LOCAL: International Call for Better Local Treatment of Rare/Hard-to-Treat Cancers
Deadline: 18 Jun 2026International consortium funding (5 European charities)INTER-LOCAL: International Funding Call for Local Treatment Strategies in Rare and Hard-to-Treat Cancers
Deadline: 18 Jun 2026
Does this grant match your research?
Sign up free to get a personalised match score and weekly alerts for grants like this.
Get started free